Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

151 results about "Retinal pigment epithelium" patented technology

The pigmented layer of retina or retinal pigment epithelium (RPE) is the pigmented cell layer just outside the neurosensory retina that nourishes retinal visual cells, and is firmly attached to the underlying choroid and overlying retinal visual cells.

Methods of Culturing Retinal Pigmented Epithelium Cells, Including Xeno-Free Production, RPE Enrichment, and Cryopreservation

The production of high quality retinal pigmented epithelium (RPE) cells is necessary for research and potential therapeutic uses. Especially desirable are methods for the production of RPE cells using xeno-free culture conditions. Disclosed herein are novel methods for the production of RPE cells from pluripotent cells with high yields, including xeno-free production methods. Also provided are methods of efficiently isolating RPE cells from cultures containing heterogeneous cell types, allowing for substantially pure RPE cell cultures to be established. Additionally, novel methods for the cryopreservation of RPE cells are provided.
Owner:UNIV OF SOUTHERN CALIFORNIA +1

Optical devices and methods for selective and conventional photocoagulation of the retinal pigment epithelium

The present invention provides devices and methods for applying radiation to the retina of a patient. In one embodiment, an apparatus includes a radiation source for generating a radiation beam suitable for absorption by retinal pigment epithelial cells. One or more optical components are included to direct the beam onto the retina. A scanner is optically coupled to the radiation source to control movement of the beam in two dimensions to allow a scan over the retina. A controller applies control signals to the scanner to adjust beam movement to illuminate a plurality of retinal locations in a temporal sequence according to a predefined pattern. The device can be operated in one mode to effect selective targeting of retinal pigment epithelial cells, or in another mode to effect thermal photocoagulation of the retina.
Owner:THE GENERAL HOSPITAL CORP

Vessel-based registration method for eye fundus image and SD-OCT projection image

The invention discloses a vessel-based automatic registration method for an eye fundus image and a spectral-domain optical coherence tomography (SD-OCT) projection image, belonging to the technical field of image processing. The method comprises the following steps: performing tissue layer segmentation on an input SD-OCT image, locating the upper boundary of a photoreceptor inner-segment / outer segment (IS-OS) layer and the lower boundary of a retinal pigment epithelium (RPE), generating an SD-OCT projection image according to the upper boundary of the IS-OS layer and the lower boundary of an RPE, and segmenting the SD-OCT projection image by using an improved level set method; segmenting a colored eye fundus image by using a morphology multi-scale top hat method; searching for the local maximum value of a maximum similar function by using an iteration blocking method to extract a control point, and calculating an affine variation coefficient according to the control point to realize registration of the SD-OCT projection vessel image and the colored eye fundus image. As proved by an experimental result, the image registration accuracy is high in different modes.
Owner:NANJING UNIV OF SCI & TECH

Modalities for the treatment of degenerative diseases of the retina

This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
Owner:ADVANCED CELL TECH INC

Compound subretinal prostheses with extra-ocular parts and surgical technique therefore

InactiveUS20070250135A1Minimize damageHighly controlled introductionElectrotherapyEye surgeryRetinal implantRetinaculotomy
In a method for introducing a retinal implant to a position within a subretinal region of an eye, the following steps are performed: a) preparing a fornix-based scleral flap at a distance from the limbus; b) detaching the retina by subretinal injection of balanced salt solution, from the vitreous cavity and creating a localized bubble in the area of the scleral flap; c) performing in the upper hemisphere of the eye a peripheral retinotomy and detaching a part of the retina; d) advancing the implant into the subretinal space and placing an inner portion of said implant on the retinal pigment epithelium onto the desired position; and e) closing the sclera flap.
Owner:RETINA IMPLANT

Modalities for the treatment of degenerative diseases of the retina

This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
Owner:ADVANCED CELL TECH INC

Improved modalities for the treatment of degenerative diseases of the retina

ActiveUS20060031951A1Increased ability to preventReduce complexityBiocideSenses disorderEmbryoCell based
This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
Owner:ADVANCED CELL TECH INC

Methods for producing retinal tissue and retina-related cell

The invention provides a method for producing a retinal tissue by (1) subjecting pluripotent stem cells to floating culture in a serum-free medium containing a substance inhibiting the Wnt signal pathway to form an aggregate of pluripotent stem cells, (2) subjecting the aggregate to floating culture in a serum-free medium containing a basement membrane preparation, and then (3) subjecting the aggregate to floating culture in a serum-containing medium. The invention also provides a method for producing an optic-cup-like structure, a method for producing a retinal pigment epithelium, and a method for producing a retinal layer-specific neural cell.
Owner:SUMITOMO CHEM CO LTD +1

Treatments for retinal disorders

The present invention relates to the use of cyclic oligosaccharides as chemical complexants of lipofuscin bisretinoids (A2E) to prevent and treat eye (i.e., retinal or macular) disease. Monomeric, dimeric, multimeric, or polymeric oligosaccharide rings act as pharmacologic agents to prevent and treat ophthalmologic disorders triggered by the accumulation of lipofuscin in the retinal pigment epithelium (RPE), which occurs as a consequence of either genetic disorders, such as Stargardt Disease (SD) and Best Disease (BD), or aging, such as Age-Related Macular Degeneration (AMD), or other diseases, such as retinitis pigmentosa, and cone-rod dystrophy.
Owner:CORNELL UNIVERSITY

Method for Treatment of Macular Degeneration

Provided is a method of treating or preventing age-related macular degeneration (AMD) in a patient subject to, or symptomatic of the disease, wherein the method comprises restoring normal lysosomal pH (pHL), or acidifying an abnormally elevated pHL, thus decreasing or preventing a damaging accumulation of lipofuscin or waste products in the retinal pigment epithelium (RPE) cells of the eye of the patient. Further, this method is achieved by elevating cAMP by administering or stimulating receptors coupled to a Gs protein in an amount sufficient to decrease the elevated pHL or restore acidity of said lysosomes, specifically by administering or stimulating receptors comprising D1-like dopamine receptors by the use of D1-like dopamine receptor agonists. Methods for selecting and quantifying the effectiveness of drugs to restore pHL and determine outer segment clearance rates is also provided using a high through-put screening protocol.
Owner:MITCHELL CLAIRE +1

Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells

Provided are methods and compositions for maintaining the viability of photoreceptor cells and / or retinal pigment epithelial cells in a subject with an ocular disorder including, for example, age-related macular degeneration (AMD) (e.g., dry or neovascular AMD), retinitis pigmentosa (RP), or a retinal detachment. The viability of the photoreceptor cells and / or the retinal pigment epithelial cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells, thereby minimizing the loss of vision or visual function associated with the ocular disorder.
Owner:VAVVAS DEMETRIOS +3

Image processing apparatus, control method thereof, and program

An image processing apparatus including a storage unit configured to store tomographic images in relation to fundus of an examined eye; a detection unit configured to detect a boundary of retinal pigment epithelium and an inner limiting membrane from each of the images and to detect a part where the boundary is discontinuous; a determination unit configured to determine a surface of a sclera model for each of the images by use of the boundary and the inner limiting membrane; a generation unit configured to generate a sclera model including an optic papilla periphery by use of the surface of the sclera model and the part where the boundary is discontinuous; a combining unit configured to combine each of the images and the sclera model to generate a combined image; and a display unit configured to display the combined image generated by the combining unit, is provided.
Owner:CANON KK

Method for preparing retinal pigment epithelia

The invention discloses a method for preparing retinal pigment epithelia. According to the method, stem cells are induced by utilizing a liver X receptor (LXR) activating agent to be differentiated into the retinal pigment epithelia. Compared with the prior art, the method for inducing the stem cells to be differentiated into the retinal pigment epithelia by utilizing the LXR receptor activating agent has the advantages that: a feed layer is not used, so that potential risks caused by an animal source feed layer are avoided; and the differentiation efficiency can be improved, and the differentiation time can be shortened.
Owner:THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA

Optical devices and methods for selective and conventional photocoagulation of the retinal pigment epithelium

The present invention provides devices and methods for applying radiation to the retina of a patient. In one embodiment, an apparatus includes a radiation source for generating a radiation beam suitable for absorption by retinal pigment epithelial cells. One or more optical components are included to direct the beam onto the retina. A scanner is optically coupled to the radiation source to control movement of the beam in two dimensions to allow a scan over the retina. A controller applies control signals to the scanner to adjust beam movement to illuminate a plurality of retinal locations in a temporal sequence according to a predefined pattern. The device can be operated in one mode to effect selective targeting of retinal pigment epithelial cells, or in another mode to effect thermal photocoagulation of the retina.
Owner:THE GENERAL HOSPITAL CORP

Macs-based purification of stem cell-derived retinal pigment epithelium

Provided herein are methods of enriching a retinal pigment epithelium (RPE) cell population derived from stem cells. Such a method may comprise removing contaminating cells through the depletion of CD24 positive cells, CD56 positive cells, and / or CD90 positive cells from a starting population of RPE cells.
Owner:FUJIFILM CELLULAR DYNAMICS INC

Compositions and methods for treating retinal degradation

The present disclosure relates to compositions and methods for treating retinal damage and / or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and / or a nucleoside or nucleotide reverse transcriptase inhibitor.
Owner:UNIV OF KENTUCKY RES FOUND

Image processing apparatus and method thereof

An image processing apparatus acquires a tomographic image of an eye to be examined. The image processing apparatus quantifies a distortion in a region determined from the tomographic image. The region includes a photoreceptor layer or a retinal pigment epithelium.
Owner:CANON KK

Use of derived polypeptide series of pigment epithelium derived factors in ischemic myocardium protection

The invention discloses a use of a derived polypeptide series of pigment epithelium derived factors in ischemic myocardium protection. The polypeptide is derived from the pigment epithelium derived factors, and every amino acid sequence in the polypeptide includes at least eighteen continuous amino acid residues. The PEDF derived functional peptide has good function advantages, and has remarkablecardiac muscle tissue capillary tube stabilization, vascular leakage prevention, myocardial cell protection and cardiac muscle tissue inflammation prevention effects.
Owner:董红燕

Device and method for treatment of retinal detachment and other maladies of the eye

The present invention relates generally to a device and method for the treatment of retinal detachment, ocular hypertension and glaucoma, and increasing the amplitude of accommodation. In an illustrative embodiment, the device includes a tapered, mesh tube. Once the device is within the sclera, the mesh expands to deform the sclera. When the device is placed within the posterior sclera for the treatment of a retinal tear, the device expands deforming the sclera so that the retinal pigment epithelium comes in contact with the retinal tear to seal the tear. For the treatment of ocular hypertension, glaucoma and to increase the amplitude of accommodation, the device is placed within the anterior sclera over the posterior plicata of the ciliary body, which upon expansion causes the underlying ciliary body to deform, resulting in traction on the trabecular meshwork and deformation of the ciliary body, which causes lowering of intraocular pressure, and increases the amplitude of accommodation in patients with ocular hypertension or decreased accommodation.
Owner:SCHACHAR IRA H +1

Methods of producing rpe cells

ActiveUS20150299653A1Fast and economically efficient scale-upFacilitate scientificBiocideCulture processClinical gradeLaminin
The present disclosure relates to the use of laminin-521 in obtaining retinal pigment epithelium (RPE) cells. Pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in totally defined and xeno-free conditions. A first cell culture medium contains a growth factor, and a second cell culture medium does not contain growth factor. The stem cells are first exposed to the first cell culture medium, then exposed to the second cell culture medium for a longer time period. After a number of weeks, clinical grade RPE cells are obtained from the stem cells.
Owner:BIOLAMINA

Methods and compositions for preserving the viability of photoreceptor cells

Provided are methods and compositions for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering a neuroprotective agent, for example, a substance capable of suppressing endogenous calcineurin or constitutively active calcineurin, inhibiting cleavage of calcineurin to constitutively active calcineurin, and / or directly or indirectly antagonizing calcineurin or constitutively active calcineurin (and combinations thereof), to a mammal having an eye with retinal detachment. The neuroprotective agent maintains the viability of the photoreceptor cells until such time that the retina becomes reattached to the underlying retinal pigment epithelium and choroid. The treatment minimizes the loss of vision, which otherwise may occur as a result of retinal detachment.
Owner:MASSACHUSETTS EYE & EAR INFARY

Retinal cell grafts and instrument for implanting

Surgical instruments, surgical techniques, retinal cell grafts, retinal cell and tissue isolation techniques, and a method for transplanting retinal cells, including photoreceptors, and / or retinal pigment epithelium, with the cells in the isolated tissue having their normal cell to cell configuration are disclosed.
Owner:HUGHES STEPHEN E

Method for inducing human embryonic stem cells to be differentiated into retinal pigment epitheliums (RPE) in vitro

The invention relates to a method for inducing human embryonic stem cells to be differentiated into retinal pigment epitheliums (RPE) in vitro, and belongs to the biology technical field. The pure RPEs can be obtained through one-time passage by means of induced differentiation. Compared with the prior art, the differentiation time from the human embryonic stem cells into the RPEs is shortened. By the adoption of the method, a new approach and guidance are provided for induced directional differentiation of the human embryonic stem cells into the pigment epitheliums.
Owner:TONGJI UNIV

Retinal pigment epithelial stem cells

The present invention relates to a retinal pigment epithelial stem cell isolated from a posterior region of the retinal pigment epithelium of an adult mammal. The invention also relates to a method of inducing differentiation of retinal epithelial stem and progenitor cells in vitro, wherein the cells of the invention are highly plastic, multipotential stem cells. The invention also includes methods for the treatment of retinal diseases and vision loss involving the transplantation of retinal pigment epithelial stem cells or cells differentiated from retinal pigment epithelial stem cells to the retina of a patient in need of treatment.
Owner:REGENERATIVE RES FOUND

Methods for preserving photoreceptor cell viability following retinal detachment

Provided are methods for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering a hydrophilic bile acid (e.g., UDCA or TUDCA) to a mammal having an eye with a detached retina. Administration of the hydrophilic bile acid maintains the viability of the photoreceptor cells until such time that the retina becomes reattached to the underlying retinal pigment epithelium and choroid, thereby minimizing the loss of vision or visual acuity, which otherwise may occur as a result of the retinal detachment.
Owner:MASSACHUSETTS EYE & EAR INFARY

Culture solution for retinal pigment epitheliums and preparation method and application thereof

The invention provides a culture solution for retinal pigment epitheliums (hESC-RPE). The culture solution is characterized in that the culture solution contains, 96-97.5 volume fractions of a basic culture medium, 1 volume fraction of non-essential amino acids (NEAA), 1 volume fraction of L-glutamine, 0.5-21 volume fractions of an N2 additive, a component a and a component b. The invention further provides a preparation method of the culture solution and a method for culturing the retinal pigment epitheliums (hESC-RPE) by using the culture solution. Compared with existing culture media, the culture medium of the culture solution is simple composition, the costs are lower, no ethical problem is related, and cell proliferation can be promoted.
Owner:INST OF ZOOLOGY CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products